A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis

October 3, 2025 updated by: SynAct Pharma Aps

A Randomized, Double Blind, Placebo-controlled, Dose Response, Phase II, Multicentre Trial to Evaluate the Efficacy and Safety of Oral AP1189 Administered at the Doses of 40, 70, or 100 mg for 12 Weeks in Combination With Methotrexate, in DMARD-naïve Participants With Early Rheumatoid Arthritis and Active Inflammation.

The study is a randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination with methotrexate, in DMARD-naïve participants with early rheumatoid arthritis and active inflammation.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The purpose of the trial is to evaluate the efficacy, safety and tolerability of 12 weeks daily treatment of oral AP1189 at the doses of 40, 70, or 100 mg in combination with oral MTX compared to oral MTX alone.

The aim is to have 240 participants randomized to one of the 4 treatment groups, in a 1:1:1:1 ratio and treated with both AP1189/Placebo and MTX.

Study Type

Interventional

Enrollment (Estimated)

240

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Signed and dated informed consent obtained before undergoing any trial-specific procedure.
  • Participants with definite RA diagnosis according to the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria.
  • Disease duration no longer than 6 months from diagnosis at the time of Baseline Visit and with a history of RA symptoms which does not exceed 18 months.
  • Participants must be naïve to any Disease-modifying anti-rheumatic drugs (DMARDs)
  • Participants with at least 6/68 tender and 6/66 swollen joints at Screening Visit and Baseline.
  • Participants with "high" disease activity as documented by a Disease Activity Score 28 (DAS28) (C-Reactive Protein - CRP) index score > 5.1 at screening, and Clinical disease activity index (CDAI) >22 at Screening Visit and Baseline.
  • Participants with serum high sensitive C-Reactive Protein (hsCRP) ≥3 mg/L at the time of screening.
  • Participants positive for serum rheumatoid factor (RF), AND/OR anti-cyclic citrullinated peptide antibodies (anti-CCP). If seronegative RA, hsCRP ≥6 mg/L at the time of screening.
  • Willing and able to comply with the scheduled study visits, the treatment plan, and all study procedures.
  • Females of childbearing potential must have a negative pregnancy test at screening and again at baseline.
  • Sexually active female participants of childbearing potential and male participants are excluded if not practicing two different methods of birth control with their partner during the study and for 90 days after the last dose of study drug or who will not remain abstinent during the study and for 90 days after the last dose.

Exclusion Criteria:

  • Functional class IV of Global Functional Status in RA, as defined by the ACR Classification.
  • Rheumatic autoimmune disease other than RA, i.e. systemic lupus erythematosus, mixed connective tissue disease, scleroderma, polymyositis, or significant systemic involvement secondary to RA.
  • Current inflammatory joint disease other than RA.
  • Non-inflammatory type of musculoskeletal condition that in the Investigator's opinion is symptomatic and/or severe enough to interfere with the subject's primary diagnosis of RA or the evaluation of the effect of the study drug.
  • Gastrointestinal diseases known to interfere with the absorption or excretion of medications.
  • Severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, metabolic, endocrine, pulmonary, cardiac or neurologic disease.
  • Malignancy active during the 12 months preceding the Screening Visit.
  • Acute hepatitis, chronic hepatitis, or detection of any unexplained elevation of serum ALT or AST greater than 1.5-fold ULN, at least twice in the 6 months before the Screening Visit) or HIV infection.
  • History of alcohol or drug abuse during the 12 months preceding the Screening Visit.
  • Vaccination with live vaccines during the 6 weeks preceding the Screening Visit.
  • Haemoglobin <9 g/dL or Haematocrit <30% at the Screening Visit
  • White blood cell (WBC) count <3.0 x 109/L at the Screening Visit.
  • Absolute neutrophil count <1.2 x 109/L at the Screening Visit.
  • Platelet count <100 x 109/L at the Screening Visit.
  • Serum alkaline-phosphatase, or gamma-glutamyl-transferase greater than 3-fold ULN; alanine aminotransferase, or aspartate aminotransferase, or total bilirubin greater than 2-fold ULN At the Screening Visit.
  • Estimated creatinine clearance less than 45 mL/min/1.73 m2 (MDRD) at the Screening Visit.
  • 12-lead electrocardiogram (ECG) with abnormal clinically significant findings, as judged by the Investigator, at the Screening Visit.
  • Positive QuantiFERON-in-Tube test (QFG-IT).
  • Use of hydroxychloroquine during the 30 weeks preceding the Screening Visit.
  • Treatment with any systemic or intraarticular corticosteroid within 6 weeks before the Screening Visit.
  • Intermittent use of nonsteroidal anti-inflammatory drugs (NSAIDs). Use of NSAIDs is allowed if used in a stable dose regimen for at least 4 weeks prior to the Screening Visit.
  • Use of other investigational drugs/treatments, or enrolment in a clinical trial during the 6 months preceding the Screening Visit.
  • Any other clinically relevant disease and condition that, in the opinion of the Investigator, may jeopardize efficacy or safety assessments or may compromise the subject's safety during trial participation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: AP1189 40 mg
12 weeks daily treatment of oral AP1189 40 mg as add-on to Methotrexate (MTX)
Drug: AP1189, 40 mg
AP1189 tablets for oral use
Experimental: AP1189 70 mg
12 weeks daily treatment of oral AP1189 70 mg as add-on to Methotrexate (MTX)
Drug: AP1189, 70 mg
AP1189 tablets for oral use
Experimental: AP1189 100 mg
12 weeks daily treatment of oral AP1189 100 mg as add-on to Methotrexate (MTX)
Drug: AP1189, 100 mg
AP1189 tablets for oral use
Experimental: Placebo
12 weeks daily treatment of oral AP1189 matching placebo as add-on to Methotrexate (MTX)
Drug: AP1189 matching placebo
AP1189 tablets for oral use

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Disease Activity Score 28 (DAS28)-C-Reactive Protein (CRP)
Time Frame: Week 12
Absolute change from baseline in DAS28-CRP at Week 12
Week 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

SynAct Pharma Aps

Collaborators

NBCD A/S

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2024

Primary Completion (Estimated)

December 1, 2025

Study Completion (Estimated)

December 1, 2025

Study Registration Dates

First Submitted

October 31, 2024

First Submitted That Met QC Criteria

October 31, 2024

First Posted (Actual)

November 4, 2024

Study Record Updates

Last Update Posted (Estimated)

October 6, 2025

Last Update Submitted That Met QC Criteria

October 3, 2025

Last Verified

October 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SynAct-CS008

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe